Abstract
Chronic pain presents a major challenge in contemporary medicine, given the limited effectiveness and numerous adverse effects linked to available treatments. Recognizing the potential of the cholinergic pathway as a therapeutic target, the present work evaluates the antinociceptive activity of a combination of Cris-104, a novel α4β2* receptor agonist, and donepezil, a central anticholinesterase agent. Isobolographic analysis revealed that equimolar combination was approximately 10 times more potent than theoretically calculated equipotent additive dose. Administration of Cris-104 and donepezil combination (3 μmol/kg) successfully reversed hyperalgesia and mechanical allodynia observed in rats subjected to spinal nerve ligation (SNL). The combination also modulated neuroinflammation by reducing astrocyte activation, evident in the decreased expression of glial fibrillary acidic protein (GFAP) in the spinal cord. The observed synergism in combining a nicotinic receptor agonist with an anticholinesterase agent underscores its potential for treating chronic pain. This alternative therapeutic distinct advantage, including dose reduction and high selectivity for the receptor, contribute to a more favorable profile with minimized adverse effects.
Funding Information
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) (#E-26/200.881/2021)
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq,) (#E-26/200.881/2021)
  • Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (#E-26/200.881/2021)
  • Cristália Produtos Químicos e Farmacêuticos Ltda (#E-26/200.881/2021)

This publication has 29 references indexed in Scilit: